Heidbreder Christian sold $707K of INDV

Heidbreder Christian (Chief Scientific Officer) sold 18,586 shares of Indivior Pharmaceuticals, Inc. (INDV) at $38.06 ($0.71M total) on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Heidbreder Christian
Published Jun 12, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INDV
Neutral
high confidence
Mentioned
$INDV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INDVNeutralLow
01

Why it matters

The disclosure provides a fresh, primary-source datapoint on insider activity, but it does not include new operational, clinical, regulatory, or financial guidance.

02

Market read

Useful for monitoring insider behavior, but unlikely to drive a fundamental repricing without accompanying company-specific catalysts.

03

What to watch

Traders may focus on the sale size, but the key nuance is the 10b5-1 structure and the post-transaction holdings (227,923 shares), which can indicate continued long-term exposure.

Relevance 4/10Novelty 8/10Timing: SEC Form 4 filed June 12 (sale dated June 11)

Background

The article is an SEC EDGAR Form 4 insider transaction for Indivior Pharmaceuticals, Inc.

Company-level read

Ticker impact

$INDVNeutralHigh confidence
Context

Indivior CSO Christian Heidbreder sold 18,586 shares (~$707K) via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale with a stated 10b5-1 pre-arranged plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; the disclosure could be largely mechanical rather than a bearish signal.

Key entities

  • Indivior Pharmaceuticals, Inc.

    Company whose insider transaction was reported on SEC Form 4.

  • Christian Heidbreder

    Chief Scientific Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SUPNMed

Supernus undervalued after Indivior merger, says Bank of America

Bank of America initiated coverage of Supernus Pharmaceuticals (SUPN) with a 'buy' rating and $47 price target, citing its merger with Indivior. The combined entity is expected to have a broader portfolio and stronger earnings potential. Bank of America forecasts 6% annual revenue and EPS growth over five years, with legacy Supernus products driving two-thirds of revenue growth.

$SUPNHighAI 9/10

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

Supernus Pharmaceuticals (SUPN) and Indivior completed their merger, creating Supernus, Inc. The combined company will trade on Nasdaq under 'SUPN' starting November 3, 2026. The merger enhances financial flexibility, expands the CNS-focused portfolio, and positions the company for long-term growth. Former Indivior shareholders will receive a $1 billion cash dividend, financed by debt and existing cash.

$INDVHighAI 8/10

Why Indivior Pharmaceuticals Stock Topped the Market Today

Indivior Pharmaceuticals (NASDAQ:INDV) shares rose 3% on its last day as a standalone company after completing a merger with Supernus Pharmaceuticals (NASDAQ:SUPN). The combined company, to be named Supernus, aims for $125M in annual cost synergies, with Indivior shareholders owning 56.5% of the new entity.

$SUPNHighAI 8/10

Supernus Pharmaceuticals Completes Merger with Indivior Pharmaceuticals

Supernus Pharmaceuticals (SUPN) completed its merger with Indivior Pharmaceuticals on November 2, 2026, forming Supernus, Inc. The combined company has an 11-product portfolio and headquarters in Rockville, Maryland. Supernus stockholders received 1.5401 Indivior shares per Supernus share. The company borrowed $650 million to fund a $1 billion dividend to Indivior stockholders.

$INDVHighAI 9/10

Indivior Pharmaceuticals, Inc. (INDV): Completion of Acquisition or Disposition of Assets

Indivior Pharmaceuticals, Inc. (INDV) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader · Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flex